ENPP2 and pulmonary fibrosis: Until now, clinical trials testing the potential use of ATX and LPA1 axis inhibitors in humans have been conducted predominantly on idiopathic pulmonary fibrosis and systemic sclerosis (NCT03798366, NCT01766817, NCT04308681).